Champions Oncology reports Q4 revenue $13.1M (+2% YoY); full-year record $53.9M but operating loss widens

CHAMPIONS ONCOLOGY, INC.

Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.
Full-year operating loss $5.3M vs income $607M; adjusted EBITDA loss $1.3M vs +$3.1M.
Gross margin fell to 44% (Q4) and 45% (FY) from 52% in prior-year periods due to study cancellations.
Cash $10.1M, no debt; CFO projects return to profitability in H2 of current fiscal year.
Announced formation of wholly owned biotech subsidiary Corellia AI for therapeutic drug discovery.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported fiscal year ended April 30, 2023 results: revenue $53.9 million.

Period: fiscal year ended April 30, 2023
Revenue: $53.9 million
Result: reported results

Exact text from the filing

Total revenue for fiscal year 2023 was $53.9 million, an increase of 10%, compared to $49.1 million for fiscal year 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported three months ended April 30, 2023 results: revenue $13.1 million.

Period: three months ended April 30, 2023
Revenue: $13.1 million
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of fiscal 2023 was $13.1 million, an increase of 2%, compared to $12.9 million for the same period last year.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-025452

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.